regdanvimab (CT-P59 Celltrion) vs. placebo - COVID 19 outpatients NA risk of bias
risk of bias not assessable
ruxolitinib vs. placebo - COVID-19 severe or critically NA risk of bias
risk of bias not assessable
anticoagulation, intermediate prophylactic dose vs. anticoagulant, prophylactic dose - COVID-19 severe or critically some concern in risk of bias
hydroxychloroquine vs. standard of care - COVID 19 outpatients some concern in risk of bias
azithromycin vs. standard of care - COVID-19 mild to moderate some concern in risk of bias
convalescent plasma treatment vs. placebo - COVID-19 severe or critically low risk of bias
anticoagulant, curative dose vs. control - COVID-19 severe or critically some concern in risk of bias
Conclusive (statistically conclusive): statistically demonstrated that is statistically significant with a strict control of overall risk of type 1 error, does not take into account the risk of bias; inconclusive: not nominally statistically significant; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error
This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.
![]() |
![]() |
![]() |
-
About
-
Our approach
-
Credits
-
RSS
Made with in Lyon
-
Contact us
-
Privacy policy
-